Loading...
•
Sep 30, 2022
Tenaya Therapeutics Q3 2022 Earnings Report
Reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
Key Takeaways
Tenaya Therapeutics reported its Q3 2022 financial results, highlighting the extension of its cash runway to mid-2024 and the commencement of dosing in the Phase 1 clinical trial of TN-301. The company ended the quarter with $149.5 million in cash, cash equivalents and investments.
Extended cash runway to mid-2024 through prioritization of R&D and manufacturing expenditures, and stringent management of future headcount growth.
Commenced dosing in Phase 1 clinical trial of TN-301, with data expected in 2023.
Plans to submit TN-201 IND to the FDA by year end 2022.
Received notification from the USPTO of the allowance of U.S. Application No. 17/731,949, which covers small molecule HDAC6 inhibitors, including lead compound TN-301.
Tenaya Therapeutics
Tenaya Therapeutics
Forward Guidance
Tenaya expects existing funds to extend the company’s cash runway to mid-2024.